Search
BioVenture VoiCes Episode 23: a16z's Vineeta Agarwala
Still a practicing physician today, Vineeta Agarwala describes her educational background and early career, including experiences at the...
Jul 28, 2025
AI x Bio Summit: Proscia CEO David West describes how AI in pathology is not just helping pathologists find disease, but can also help get the right drug to the right patient
He describes how computing power in pathology is augmenting the work that pathologists traditionally do, but also is becoming an...
Jul 24, 2025
Monte Rosa Therapeutics' CEO Markus Warmuth updates us on the company's progress in developing molecular glue degraders
The company, which recently had a paper earn a spot on the cover of Science, is progressing ahead with both I&I and oncology indications....
Jul 24, 2025
Abivax CEO Marc de Garidel discusses Obefazimod's phase 3 trial result in ulcerative colitis, and what is next for the company
He covers the mechanism of action, this week's efficacy and safety data, what it might mean for the maintenance trial that will read out...
Jul 24, 2025
AI x Bio Summit: Recursion's Chief R&D Officer & CCO Najat Khan describes how the company leverages AI - including in both the dry lab and the wet lab, and all through clinical trials
She describes Recursion's work, and what the acquisition of Exscientia has brought to the company. Plus, how AI can not only help with...
Jul 23, 2025
After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of Replimune walks us through the program's timeline and history, and what this might mean for its future
CEO Sushil Patel walks us through the decisions behind the design of the IGNYTE phase 1/2 study and the ongoing IGNYTE-3 study, he gives...
Jul 23, 2025
AI x Bio Summit: The CEO of Alto Neuroscience, which is working on precision medicine for neuroscience, talks about how the company is using AI and machine learning in its development programs
Amit Etkin says Alto Neuro is trying to use machine learning to understand signals from the complexity of the brain, and the company is...
Jul 22, 2025
NYSE Strategist Eric Criscuolo shares his take on the markets and biotech sentiment
He discusses the importance of interest rates to high risk sectors like biotech, and comment on how our sector has not performed lately...
Jul 22, 2025
AI x Bio Summit: The Co-Founder and Head of Machine Learning at Dyno Therapeutics describes how his company is using AI to design better capsids
Sam Sinai talks about how capsids are being more precisely designed today, which is allowing drug developers to better target them to...
Jul 22, 2025
RBC's Healthcare Desk Strategist Chris McCarthy discusses biotech sentiment, and positioning around key events and catalysts that are upcoming
He highlights recent M&A, but also notes how the sector has not been reliant on deals like it has in the past. Plus, discussing how...
Jul 22, 2025
AI x Bio Summit: Nimbus Therapeutics' new CEO and President of R&D describe how AI is, an isn't, used in the company's R&D process
CEO Abbas Kazimi and President of R&D Peter Tummino discuss how AI integrates into their discovery and clinical development work, and...
Jul 22, 2025
Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA
He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the...
Jul 22, 2025
Cambridge, MA based Avalyn Pharma is developing a novel inhaled formulation of pirfenidone and other medicines for pulmonary fibrosis - it just raised a $100M (up round) series D financing
CEO Lyn Baranowski describes the therapy and demonstrates the nebulizer that delivers it, and explains how Avalyn's method is designed increase the dose patients can take vs oral therapies and, therefore, increase the therapeutic value.
Jul 22, 2025
Jon Norris shares highlights from his 2025 Mid-Year Venture Healthcare Report
He discusses trends in deal size, therapeutic focus, IPOs, and more. DOWNLOAD THE FULL REPORT #sponsored
Jul 21, 2025
On a visit through London today, NodThera's CEO Dan Swisher discusses the company's brain-penetrant NLRP3 platform, including an asset that's in phase 2 for weight loss
He discusses the science behind NLRP3, and describes why he thinks NodThera's brain penetration differentiates it from other programs...
Jul 21, 2025
Biotech CEO Sisterhood: As CEO, Sophie Kornowski sold Boston Pharmaceuticals to GSK earlier this year for up to $2 billion. She shares her thoughts on the biopharma business and leadership
Interviewed by Sisterhood editorial board member Daphne Zohar, Sophie Kornowski shares her keys to creating great assets,...
Jul 18, 2025
Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline
He describes the benefits of prime editing, walks us through human proof-of-concept data that was announced in a patient with Chronic...
Jul 17, 2025
Kailera Therapeutics' partner Hengrui announced positive p3 results for its GLP1/GIP agonist in China - biotech veteran and Kailera CEO Ron Renaud walks us through the company's obesity space strategy
He describes why Kailera chose to in-license a GLP1/GIP specifically, and describes where he sees this asset placing in the competitive...
Jul 16, 2025
Southampton professor, and Curve Therapeutics' CSO, Ali Tavassoli describes the unique properties of cyclic peptides and why he believes Curve's cell-based method to drug discovery makes it different
He describes the properties that make cyclic peptides unique compared to small molecules and antibodies, and how Curve's approach is...
Jul 15, 2025
Southampton, UK based Curve Therapeutics believes its mammalian cell-based 'Microcycle' platform is a better way to do drug discovery - lead programs from it target HIF-1/HIF-2 and ATIC
Co-Founder and CEO Simon Kerry discusses being in Southampton, and why he believes the 'Microcycle' platform beats screening in...
Jul 15, 2025
.png){kind=logo}
